Increased Risk of Hepatocellular Carcinoma in Patient with Inflammatory Bowel Disease and Hemochromatosis: A Case Report by Roselli, Jenny et al.
Gastroenterology & Hepatology International Journal 
ISSN: 2574-8009 
 
Increased Risk of Hepatocellular Carcinoma in Patient with Inflammatory Bowel Disease and 
Hemochromatosis: A Case Report 




Increased Risk of Hepatocellular Carcinoma in Patient with 




Roselli R, Triboli E, Macrì G and Tarocchi M* 
1Department of Biomedical, Sperimental and Clinical Sciences, University of Florence, 
Florence, Italy  
2San Donato Hospital, Arezzo, Italy 
 
*Corresponding author: Tarocchi Mirko, Department of Biomedical, Sperimental and 




Inflammatory bowel diseases could be associated with extra-intestinal manifestation; in this report we describe the case 
of a patient with ulcerative colitis who was diagnosed with genetic hemochromatosis (homozygosity for C282Y in the 
HFE gene) after a colitis relapse with high levels of serum ferritin (2000 ng/mL). After the genetic diagnosis patient 
underwent to an upper abdomen US with CEUS, with evidence of a 2 cm nodule in VIIs, suggestive for hepatocellular 
carcinoma, then confirmed with MR and CT scan. Patient underwent surgical resection of the lesion with histological 
confirmation of the malignant neoplasia. A correlation between the two diseases is not clear, but inflammatory bowel 
diseases and genetic hemochromatosis have some similarity: both diseases are related with functional reduction of 
hepcidin and in both diseases the mutations are located in chromosome 6p. Furthermore, regarding therapies, there is no 
evidence that iron chelation therapies could aggravate symptoms of ulcerative colitis, instead a chronic therapy with 
mesalazine could induce a chronic liver damage, worsening the hemochromatosis related liver damage. 
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Introduction 
Inflammatory Bowel Diseases (IBD) are often 
associated with extra-intestinal manifestations (EIMs), 
which are mainly rheumatological (axial or peripheral 
spondyloarthritis, dactylitis, etc.) and/or dermatological 
(sweet syndrome, erythema nodosum, pyoderma 
gangrenosum, etc.), but can also involve the hepatobiliary 
tract. The most specific hepatobiliary disorder in IBD 
patients is primary sclerosing cholangitis, PSC (7,4% of 
IBD patients has PSC and 70% of PSC patients has IBD) [1-
5]. 
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Hereditary hemocromatosis is reported to induce liver 
damage due to iron accumulation that can lead to cancer 
[6]. In this report we describe a case of an IBD patient 
who was diagnosed with genetic hemochromatosis type 1 




A 63-years-old Italian man, who was diagnosed with 
ulcerative colitis (UC) in July 2014, was referred to our 
Centre in June 2015 for a disease relapse (bloody diarrhea 
with abdominal pain and weight loss - full Mayo score 9) 
despite oral and topical mesalazine. Laboratory tests 
showed increased pro-inflammatory values, including 
serum ferritin (2000 ng/mL). At first, we attributed the 
high levels of serum ferritin to the UC relapse, but the 
persistence of elevated values despite resolution of 
intestinal symptoms and a positive family history for 
cryptogenic liver disease, led us to further analyze the 
hepatic asset. After excluding common causes of hepatic 
damage related to high serum ferritin (NAFLD, ASH, 
metabolic syndrome, etc.), the patient underwent a 
genetic test, which showed homozygosity for C282Y in the 
HFE gene, so we were able to diagnose HFE 
hemochromatosis. The patient began iron chelation 
therapy with deferasirox 750 mg/die. An upper abdomen 
US with CEUS was performed and showed a 2 cm lesion in 
VIIs, suggestive for HCC which was confirmed with a CT 
scan and a liver MR (Figure 1). In December 2015 the 
patient underwent resection of the nodule with complete 
eradication. The patient regularly attends oncological and 
gastroenterological follow-up visits for hemochromatosis 
and ulcerative colitis at our Centre and continues specific 




Figure 1: Magnetic resonance (MR) of upper abdomen. Section passing trought the hepatocellular carcinoma in VIIs. 
Top left: hepatobiliary phase. Top right: fat suppressed phase. Down left: T1 weighted. Down right: T1 post contrast 
early arterial phase.  
 
Discussion 
The Role of Hepcidin in Hereditary 
Hemocromatosis and IBD 
In hereditary hemocromatosis, HFE gene mutations 
reduce or block hepcidin-induced internalization of 
ferroportin causing hyperabsorption of dietary iron and 
increased release of iron from macrophages to the 
bloodstream [7]. The exact connection between hepcidin 
and IBD is still unclear. Anaemia in IBD is partly due an 
increased expression of proinflammatory cytokines (TNF 
alfa, IFN alfa, IL1, IL6) and a reduced expression of 
hepcidin, which results in reduced intestinal iron 
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absorption and increased iron release from macrophages 
[8-13]. Some authors have demonstrated that hepcidin 
levels are lower in IBD patients. This could be explained 
by the hyperactivation of pro-inflammatory pathways, 
which is seen in IBD patients, that leads to a reduction in 
circulating iron and iron reserves, which consequently 
reduces or blocks hepcidin syntheses. Body iron reserves 
are, in fact, amongst the main regulators of the production 
of hepcidin. Mecklenburg et al. [14] showed that hepcidin 
levels correlated with serum ferritin levels, with a serum 
ferritin cut-off of 30 microg/L and were independent of 
disease severity [14].  
 
Is There a Genetic Correlation? 
It is now commonly accepted that inflammatory bowel 
diseases have a multifactorial pathogenesis. To have a 
positive family history is amongst the greatest risk factors 
for IBD and many IBD susceptibility genes have been 
discovered. The strongest correlation has been found 
between single nucleotide polymorphisms (SNPs) within 
the HLA region, which is localized on the short arm of 
chromosome 6 (6p21) [15-16]. Hereditary 
hemochromatosis is usually inherited in an autosomal-
recessive pattern and is associated with mutations of the 
HFE gene, which is also localized on the short arm of 
chromosome 6 (6p22.2). The physical closeness of the loci 
involved in the two diseases (6p21 e 6p22.2) are been 
suggested to have a role in the coexistance of the two 
diseases in one single patient, as described in this case 
report and in other cases in literature [17-19]. 
 
Is There a Correlation Between First Line 
Therapies for IBD (Mesalazine and Steroids) 
and an Increased Risk of HCC in HFE 
Hemochromatosis? 
An higher risk of HCC in HFE hemochromatosis 
patients is known. In our patient the IBD therapies could 
have worsened the liver damage, indeed an higher risk of 
chronic liver damage has been demonstrated in IBD 
patients ongoing chronic therapy with mesalazine [20,21]. 
 
Could Deferasirox Worsen The Symptoms of 
Ulcerative Colitis? 
There is no evidence of a correlation between iron 
chelation therapy for HFE hemochromatosis and the 





IBD patients in active treatment with mutations of 
HFE gene have an higher risk of manifestation of 
hemochromatosis and its complications: for this reason a 
follow-up of liver functions is strongly suggested.  
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